WO2006084782A1 - Verwendung von eisen(iii)-komplexverbindungen - Google Patents
Verwendung von eisen(iii)-komplexverbindungen Download PDFInfo
- Publication number
- WO2006084782A1 WO2006084782A1 PCT/EP2006/050276 EP2006050276W WO2006084782A1 WO 2006084782 A1 WO2006084782 A1 WO 2006084782A1 EP 2006050276 W EP2006050276 W EP 2006050276W WO 2006084782 A1 WO2006084782 A1 WO 2006084782A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- iron
- use according
- iii
- complex
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Definitions
- the present invention relates to novel therapeutic applications of e ⁇ sen (ll l) -Complexverb ⁇ nditch with carbohydrates or derivatives thereof, in particular with dextrins or oxidation products of dextrins, in particular for the production of medicaments for improving the immune system and / or brain performance Elsencream is the most common trace element deficiency worldwide
- E ⁇ sen (III) -ox ⁇ d is known as an active ingredient for the treatment of immune deficiency diseases, in particular AIDS
- WO 03/087 1 64 discloses iron complex compounds with hydrogenated dextrins for the treatment or prophylaxis of iron deficiency states.
- WO 02/46241 discloses eulsenic (III) -pullulan complex compounds and their use for the treatment or prophylaxis of iron deficiency states
- Iron sulfate is known to cause relatively frequently disagreeable dose-dependent side reactions, such as gastrointestinal disorders or discoloration of the teeth. Iron from iron salt compounds is subject to the passive diffusion of free iron ions. The iron can enter the circulation causing side reactions or iron intoxication. Accordingly, LD50 is also relatively low in 230 mg iron / kg white mice. The use of iron salt compounds is therefore particularly useful in the treatment of children which iron is particularly important for the development of the brain and the immune system, disadvantageous.
- the inventors therefore set themselves the task of finding well-contractual iron compounds which are suitable for improving brain performance and immune defense, in particular in children, including infants and adolescents, in one study they were able to show that complex compounds with carbohydrates, in particular with polymaltose (Maltodext ⁇ n) are particularly contractual, have a high patient comfort factor and bring about a significant improvement of the immune defense and / or the brain power.
- complex compounds with carbohydrates in particular with polymaltose (Maltodext ⁇ n) are particularly contractual, have a high patient comfort factor and bring about a significant improvement of the immune defense and / or the brain power.
- E ⁇ sen (III) -Polymaltose complex Verb ⁇ nditch only lead to a slow increase in Fer ⁇ tinapts Based on this result, they completed the present invention subject of the invention is therefore the use of E ⁇ sen (III) - Komplexverb ⁇ nditch with carbohydrates or derivatives thereof for the manufacture of a medicament for improving the immune defense and / or brain performance
- the improvement of the immune defense in the sense of the invention means a significant improvement in the immune responses, as manifested, for example, in a significant improvement in the immune response
- Tetrazolium assay (MBT) using neutropenia in an improvement of the bactericidal capacity of neutropenia (PCA) measured by the tubidimet ⁇ sche method, in an improvement of monoclonal antibodies, such as CD3, CD4, CD8 and CD56, paid for example with a BD-Fl ⁇ eßzytometer with easier
- An improvement of the brain power in the sense of the invention includes, in particular, an improvement in the cognitive functions and the emotional behavior and is expressed for example in an improvement in the short-term memory test (STM), in the long-term memory test (LTM), in the test of the progressive Mat ⁇ ces Raven, in the Welscher's Adult Intellect Scale (WAIS) and / or Emotional Coefficient (Baron EQ-I, YV Test, Teen Version)
- STM short-term memory test
- LTM long-term memory test
- WAIS Welscher's Adult Intellect Scale
- Emotional Coefficient Baron EQ-I, YV Test, Teen Version
- Carbohydrates which may be used according to the invention are preferably those in which carbohydrates are selected from the group consisting of dextranes and derivatives thereof, dextrins and derivatives thereof, and pullulan, oligomers and / or derivatives thereof are particularly preferred E ⁇ sen (III) - complex compounds with dextrins or oxidation products thereof
- Examples of the preparation of erfmdungsge responsiblyen E ⁇ sen (III) - complex compounds can be found for example in the aforementioned patent DE 1 4679800, WO 04037865 Al, US 3076798, WO 03/0871 64 and WO 02/46241, the disclosure of which should be included here vollurnfanglich especially with regard to the production process
- the term "erfmdungsgetown preferably used" dextrins is a collective name for various lower and higher polymers of D-Glucose E ⁇ nhe ⁇ ten, which in incomplete They can be further prepared by polymerization of sugars (eg WO02083739
- the dextrins include the Maltodext ⁇ ne or Polymaltosen produced by enzymatic cleavage of maize or potato starch with alpha-amylase be and the By the degree of hydrolysis expressed by the DE value (dextrose equivalent), polymaitose can also be obtained by acid hydrolysis of dextrins according to the invention.
- the preparation of the iron [111) complex compounds which can be used according to the invention is generally carried out by reaction of eicels (II) or (III) -salts, in particular E ⁇ sen (lll) -chlor ⁇ d, with the dextrins, in particular polymaitose, or oxidation products of dextrins in wass ⁇ ger alkaline solution (pH> 7) and subsequent workup.
- the preparation also succeeds in the weakly acidic pH range. However, preference is given alkaline pH values of, for example,> 1 0
- the raising of the pH preferably takes place slowly or gradually, which can be carried out, for example, by first adding a weak base, for example up to a pH of about 3, and then neutralizing it further with a stronger base Alkali or alkaline earth carbonates, bicarbonates, such as sodium and potassium carbonate or bicarbonate or ammonia.
- Strong bases are, for example, alkali or alkaline earth hydroxides, such as sodium, potassium, calcium or magnesium hydroxide
- the reaction can be favored by heating example, temperatures are used in the order of 15 ° C to the boiling point it is preferred to raise the temperature gradually For example, initially heated to about 1 5 to 70 0 C gradually increased up to boiling become
- the reaction times are for example of the order of 15 minutes to several hours, for example 20 minutes to 4 hours, for example 25 to 70 minutes, eg 30 to 60 minutes.
- the reaction times are for example of the order of 1 to 5 minutes several hours, eg 20 minutes to 4 hours, for example 25 to 70 minutes, eg 30 to 60 minutes
- the solution obtained can, for example, be cooled to room temperature and optionally diluted and optionally filtered.
- the pH can be adjusted to neutral point or slightly below it by adding acid or base, for example to values of 5 to 7
- Acids include, for example, hydrochloric acid and sulfuric acid.
- the resulting solutions are purified and can be used directly for the preparation of medicaments.
- it is also possible to isolate the iron (III) complexes from the solution for example by precipitation with an alcohol, such as an alkanol, for example ethanol. The isolation can also be carried out by spray drying.
- the purification can be carried out in a customary manner, in particular for the removal of salts, for example by reverse osmosis, such reverse osmosis being carried out before the Spray-drying or can be carried out before the direct use in medicaments
- the received E ⁇ sen (lll) -komplexe exhibit for example a
- this has the E ⁇ sen (III) -Polymaltose Komplexverb ⁇ ndung a molecular weight in the range of 20,000 to 500,000, in a preferred embodiment of 30,000 to 80,000 daltons (determined by gel permeation chromatography, for example as Geisser et al In Medic Research / Drug Res 42 (1 1 ), 1 2, 1 439- 1 452 (1 992), paragraph 2 2 5 described)
- a particularly preferred E ⁇ sen (III) -hydrox ⁇ d- Polymaltose complex compound is commercially available Maltofer ⁇ the company Vifor AG, Switzerland
- a preferred embodiment of this invention is an eilene (lil) complex compound having an oxidation product of one or more maltodextrins.
- the weight average molecular weight Mw of the complexes thus obtained is for example 30 kDa bis 500 kDa, preferably 80 to 350 kDa, particularly preferably up to 300 kDa (determined by means of gel permeation chromatography, for example as described by Geisser et al.
- the oral daily dose is, for example, between 10 and 500 mg iron / day of administration without hesitation over a period of several months to the improvement of iron status, reflected by the hemoglobin value, the Transfer ⁇ n-saturation and the ferritin value, the patients are taken
- the oral administration is preferably in the form of a tablet, a capsule, a wass ⁇ gen solution or emulsion, as granules, capsules, gels or sachets.
- solutions or emulsions is preferred, especially in children in the form of syrups or juices, drops, etc.
- the emulsions (III) -hydrox ⁇ d-dextrin complex compounds can be used with customary pharmaceutical carriers or excipients in the appropriate
- the use according to the invention can be carried out in children, adolescents and adults. It is preferably carried out for the production of a medicament for the treatment of children. Infants include infants and adolescents.
- the use according to the invention proceeds in particular by means of improving neutrophil levels, antibody levels and / or lymphocyte function , determined, for example, by the lymphocyte reaction to phytohemagglutinin
- the use according to the invention can be used for the treatment of patients with iron deficiency anemia, lack of elimination without anemia as well as patients without iron deficiency anemia or iron deficiency, preferably for the treatment of patients with iron deficiency
- Classification depends on the age and sex of the patient and can also vary individually. The classification can be made, for example, by the hemoglobin value and the value for transference saturation (%). Reference values for hemoglobin determined by flow cytometry (photometric) cyanhamiglobin method are listed, for example, by Cha ⁇ te, Institute of Laboratory Medicine and pathobiochemistry (http // www ch ⁇ te de / ⁇ lp / rout ⁇ ne / p ⁇ r ⁇ meter html) In patients without a lack of lees, the secretion is usually> 1 6%
- the aim of the comparative study was to evaluate the effects of the orally administered nitric oxide polymaltose complex (1 00 mg iron per day and placebo during 6 days per week for 8 months) on the immune responses, the hematological status, the cognitive functions and to investigate the behavioral functions in four groups of adolescents with iron deficiency anemia, with lack of skins, lack of arms and anemia (iron supplementation) and another group without iron deficiency and anemia (placebo group)
- Each group consisted of 30 subjects and there were a total of 1 20 subjects divided into the above four groups (NP, NS, ID and IDA) Test procedure:
- Venous blood was administered to all 1 20 subjects using
- the serums were from the
- TS was calculated from SFe and TIBC and as
- Percent indicated serum ferritin analyzes were performed using an Enzyme Linked Immuno Sorbent Assay (E LISA).
- Serum folate and cyanacobalamin (B l 2) were determined by standard procedures
- neutrophils and lymphocytes were separated by the one step double density gradient method and the following immunological assays were performed for all 1 20 subjects:
- MTT Nitroblue tetrazolium assay
- BCA bactericidal capacity of neutrophils
- CD56 was performed using a single-pass flow cytometer by the single-color method and as a percentage for all 1 20
- the cognitive functions and emotional behavior of the 1 20 subjects were determined according to the most commonly used tests and according to established methodology
- the school achievements of the 1 20 subjects were individually determined by a school performance test
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2006212322A AU2006212322B2 (en) | 2005-02-09 | 2006-01-18 | Use of iron(III) complex compounds |
MX2007009588A MX2007009588A (es) | 2005-02-09 | 2006-01-18 | Uso de compuestos de complejo de hierro(iii). |
CA2597154A CA2597154C (en) | 2005-02-09 | 2006-01-18 | Use of iron(iii) complex compounds |
EP06707742A EP1848446B1 (de) | 2005-02-09 | 2006-01-18 | Verwendung von eisen(iii)-komplexverbindungen |
BRPI0606974-6A BRPI0606974A2 (pt) | 2005-02-09 | 2006-01-18 | uso de compostos de complexo de ferro(iii) |
US11/815,568 US8722101B2 (en) | 2005-02-09 | 2006-01-18 | Use of iron(III) complex compounds |
PL06707742T PL1848446T3 (pl) | 2005-02-09 | 2006-01-18 | Zastosowanie kompleksowych związków żelaza(III) |
DK06707742.0T DK1848446T3 (da) | 2005-02-09 | 2006-01-18 | anvendelse af jern(III)-kompleksforbindelser |
DE502006005100T DE502006005100D1 (de) | 2005-02-09 | 2006-01-18 | Verwendung von eisen(iii)-komplexverbindungen |
AT06707742T ATE445406T1 (de) | 2005-02-09 | 2006-01-18 | Verwendung von eisen(iii)-komplexverbindungen |
JP2007554530A JP5060312B2 (ja) | 2005-02-09 | 2006-01-18 | 鉄(iii)錯化合物の用途 |
IL185020A IL185020A (en) | 2005-02-09 | 2007-08-02 | Use of three-value iron-on-metal compound compounds or on three-value iron-onset compounds with one or more maltodextrin oxidation products in the preparation of a drug to improve immune protection and / or brain function in patients without iron deficiency or iron deficiency anemia |
TNP2007000307A TNSN07307A1 (en) | 2005-02-09 | 2007-08-08 | Use of iron (iii) complex compounds |
NO20074536A NO20074536L (no) | 2005-02-09 | 2007-09-07 | Anvendelse av jern (III)-komplekssammensetninger |
HR20100027T HRP20100027T1 (hr) | 2005-02-09 | 2010-01-14 | Upotreba kompleksnih spojeva željeza (iii) |
US14/202,056 US20140187514A1 (en) | 2005-02-09 | 2014-03-10 | Use Of Iron(III) Complex Compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05100907 | 2005-02-09 | ||
EP05100907.4 | 2005-02-09 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/815,568 A-371-Of-International US8722101B2 (en) | 2005-02-09 | 2006-01-18 | Use of iron(III) complex compounds |
US14/202,056 Division US20140187514A1 (en) | 2005-02-09 | 2014-03-10 | Use Of Iron(III) Complex Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006084782A1 true WO2006084782A1 (de) | 2006-08-17 |
Family
ID=34938674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/050276 WO2006084782A1 (de) | 2005-02-09 | 2006-01-18 | Verwendung von eisen(iii)-komplexverbindungen |
Country Status (26)
Country | Link |
---|---|
US (2) | US8722101B2 (de) |
EP (1) | EP1848446B1 (de) |
JP (1) | JP5060312B2 (de) |
KR (1) | KR20070107106A (de) |
CN (1) | CN101155593A (de) |
AT (1) | ATE445406T1 (de) |
AU (1) | AU2006212322B2 (de) |
BR (1) | BRPI0606974A2 (de) |
CA (1) | CA2597154C (de) |
CR (1) | CR9300A (de) |
CY (1) | CY1109685T1 (de) |
DE (1) | DE502006005100D1 (de) |
DK (1) | DK1848446T3 (de) |
ES (1) | ES2333814T3 (de) |
HR (1) | HRP20100027T1 (de) |
IL (1) | IL185020A (de) |
MX (1) | MX2007009588A (de) |
NO (1) | NO20074536L (de) |
PL (1) | PL1848446T3 (de) |
PT (1) | PT1848446E (de) |
RU (1) | RU2359680C2 (de) |
SI (1) | SI1848446T1 (de) |
TN (1) | TNSN07307A1 (de) |
UA (1) | UA88347C2 (de) |
WO (1) | WO2006084782A1 (de) |
ZA (1) | ZA200707716B (de) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010108493A1 (en) * | 2009-03-25 | 2010-09-30 | Pharmacosmos Holding A/S | A stable iron oligosaccharide compound |
JP2012502945A (ja) * | 2008-09-19 | 2012-02-02 | ネステク ソシエテ アノニム | 乳清及び胸腺機能 |
WO2012104204A1 (en) | 2011-01-31 | 2012-08-09 | Vifor (International) Ag | Iron-carbohydrate complex compounds for the intravenous therapy of malaria |
US9376505B2 (en) | 2002-10-23 | 2016-06-28 | Vifor (International) Ag. | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007081744A2 (en) | 2006-01-06 | 2007-07-19 | Luitpold Pharmaceuticals, Inc. | Methods and compositions for administration of iron |
US11395502B2 (en) * | 2012-10-18 | 2022-07-26 | Patrick Monsivais | Formulation for iron supplements |
CN105228621A (zh) * | 2013-03-28 | 2016-01-06 | 维福(国际)股份有限公司 | 用于缺铁症状和缺铁性贫血的治疗和预防的Fe(III)络合化合物 |
KR20150078375A (ko) * | 2013-12-30 | 2015-07-08 | 한화케미칼 주식회사 | 철산화물 나노입자를 포함하는 철결핍증의 예방 또는 치료용 약학 조성물 |
FR3075001B1 (fr) * | 2017-12-14 | 2021-09-10 | Tereos Starch & Sweeteners Belgium | Utilisation des maltodextrines pour ameliorer la cognition et/ou stimuler le developpement du cerveau |
CN114288320A (zh) * | 2021-12-29 | 2022-04-08 | 珠海天翼医药技术开发有限公司 | 一种猪用口服补铁剂及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995035113A1 (de) * | 1994-06-20 | 1995-12-28 | Thomas Bruns | VERWENDUNG VON EISEN (III)-OXID (Fe2O3) BEI IMMUNSCHWÄCHE, INSBESONDERE AIDS |
WO2002046241A2 (en) * | 2000-12-07 | 2002-06-13 | Ad 'zdravlje' Farmaceutsko - Hemijska Industrija, Centar Za Istrazivanje I Razvoj | Polynuclear complex fe(iii) with pullulan oligomers, process of its obtaining, and pharmaceutical preparations on the basis of the complex |
WO2004037865A1 (de) * | 2002-10-23 | 2004-05-06 | Vifor (International) Ag | Wasserlösliche eisen-kohlenhydrat-komplexe, deren herstellung und diese enthaltende arzneimittel |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3076798A (en) * | 1961-02-23 | 1963-02-05 | Hausmann Lab Ltd | Process for preparing a ferric hydroxide polymaltose complex |
US3766165A (en) * | 1966-08-17 | 1973-10-16 | Pfizer | Polysaccharides and their preparation |
DE19734293A1 (de) * | 1997-08-08 | 1999-02-11 | Boehringer Mannheim Gmbh | Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen |
US6821547B2 (en) * | 2001-04-10 | 2004-11-23 | Danisco Usa, Inc. | Polymerization of mono and disaccharides with monocarboxylic acids and lactones |
DE60307249T2 (de) | 2002-04-09 | 2007-03-15 | Pharmacosmos Holding A/S | Eisen-dextrin verbindung zur behandlung von anämien durch eisenmangel |
-
2006
- 2006-01-18 WO PCT/EP2006/050276 patent/WO2006084782A1/de active Application Filing
- 2006-01-18 ES ES06707742T patent/ES2333814T3/es active Active
- 2006-01-18 UA UAA200708978A patent/UA88347C2/ru unknown
- 2006-01-18 RU RU2007133509/15A patent/RU2359680C2/ru not_active IP Right Cessation
- 2006-01-18 AT AT06707742T patent/ATE445406T1/de active
- 2006-01-18 DK DK06707742.0T patent/DK1848446T3/da active
- 2006-01-18 BR BRPI0606974-6A patent/BRPI0606974A2/pt not_active IP Right Cessation
- 2006-01-18 DE DE502006005100T patent/DE502006005100D1/de active Active
- 2006-01-18 KR KR1020077020249A patent/KR20070107106A/ko not_active Application Discontinuation
- 2006-01-18 MX MX2007009588A patent/MX2007009588A/es active IP Right Grant
- 2006-01-18 CN CNA2006800115263A patent/CN101155593A/zh active Pending
- 2006-01-18 PT PT06707742T patent/PT1848446E/pt unknown
- 2006-01-18 US US11/815,568 patent/US8722101B2/en not_active Expired - Fee Related
- 2006-01-18 SI SI200630432T patent/SI1848446T1/sl unknown
- 2006-01-18 EP EP06707742A patent/EP1848446B1/de active Active
- 2006-01-18 JP JP2007554530A patent/JP5060312B2/ja not_active Expired - Fee Related
- 2006-01-18 CA CA2597154A patent/CA2597154C/en not_active Expired - Fee Related
- 2006-01-18 PL PL06707742T patent/PL1848446T3/pl unknown
- 2006-01-18 AU AU2006212322A patent/AU2006212322B2/en not_active Ceased
-
2007
- 2007-08-02 IL IL185020A patent/IL185020A/en not_active IP Right Cessation
- 2007-08-08 TN TNP2007000307A patent/TNSN07307A1/en unknown
- 2007-08-09 CR CR9300A patent/CR9300A/es unknown
- 2007-09-07 ZA ZA200707716A patent/ZA200707716B/xx unknown
- 2007-09-07 NO NO20074536A patent/NO20074536L/no not_active Application Discontinuation
-
2009
- 2009-12-14 CY CY20091101333T patent/CY1109685T1/el unknown
-
2010
- 2010-01-14 HR HR20100027T patent/HRP20100027T1/hr unknown
-
2014
- 2014-03-10 US US14/202,056 patent/US20140187514A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995035113A1 (de) * | 1994-06-20 | 1995-12-28 | Thomas Bruns | VERWENDUNG VON EISEN (III)-OXID (Fe2O3) BEI IMMUNSCHWÄCHE, INSBESONDERE AIDS |
WO2002046241A2 (en) * | 2000-12-07 | 2002-06-13 | Ad 'zdravlje' Farmaceutsko - Hemijska Industrija, Centar Za Istrazivanje I Razvoj | Polynuclear complex fe(iii) with pullulan oligomers, process of its obtaining, and pharmaceutical preparations on the basis of the complex |
WO2004037865A1 (de) * | 2002-10-23 | 2004-05-06 | Vifor (International) Ag | Wasserlösliche eisen-kohlenhydrat-komplexe, deren herstellung und diese enthaltende arzneimittel |
Non-Patent Citations (2)
Title |
---|
ANDREWS N C ET AL: "Disorders of red cell iron during infancy and childhood", INTERNATIONAL JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY 1997 UNITED KINGDOM, vol. 4, no. 2, 1997, pages 171 - 180, XP009050932, ISSN: 1070-2903 * |
KOLB E: "[Relation of iron supply and iron metabolism to infectious diseases and parasitoses and the competence of the immune system]", ZEITSCHRIFT FUR DIE GESAMTE INNERE MEDIZIN UND IHRE GRENZGEBIETE ... 1 NOV 1988, vol. 43, no. 21, 1 November 1988 (1988-11-01), pages 597 - 601, XP009050945, ISSN: 0044-2542 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10519252B2 (en) | 2002-10-23 | 2019-12-31 | Vifor (International) Ag. | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
US11590097B2 (en) | 2002-10-23 | 2023-02-28 | Vifor (International) Ag | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
US11291645B2 (en) | 2002-10-23 | 2022-04-05 | Vifor (International) Ag | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
US11123321B2 (en) | 2002-10-23 | 2021-09-21 | Vifor (International) Ag | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
US9376505B2 (en) | 2002-10-23 | 2016-06-28 | Vifor (International) Ag. | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
JP2012502945A (ja) * | 2008-09-19 | 2012-02-02 | ネステク ソシエテ アノニム | 乳清及び胸腺機能 |
EP3156075A1 (de) * | 2009-03-25 | 2017-04-19 | Pharmacosmos Holding A/S | Oligosaccharid und verfahren zur herstellung davon |
US9439969B2 (en) | 2009-03-25 | 2016-09-13 | Pharmacosmos Holding A/S | Stable iron oligosaccharide compound |
WO2010108493A1 (en) * | 2009-03-25 | 2010-09-30 | Pharmacosmos Holding A/S | A stable iron oligosaccharide compound |
US10414831B2 (en) | 2009-03-25 | 2019-09-17 | Pharmacosmos Holding A/S | Stable iron oligosaccharide compound |
EA023917B1 (ru) * | 2009-03-25 | 2016-07-29 | Фармакосмос Холдинг А/С | Стабильное железо - олигосахаридное соединение |
US10865255B2 (en) | 2009-03-25 | 2020-12-15 | Pharmacosmos Holding A/S | Stable iron oligosaccharide compound |
EP3821910A1 (de) * | 2009-03-25 | 2021-05-19 | Pharmacosmos Holding A/s | Oligosaccharid und verfahren zur herstellung davon |
AU2009342799B2 (en) * | 2009-03-25 | 2014-12-18 | Pharmacosmos Holding A/S | A stable iron oligosaccharide compound |
US8815301B2 (en) | 2009-03-25 | 2014-08-26 | Pharmacosmos Holding A/S | Stable iron oligosaccharide compound |
US11851504B2 (en) | 2009-03-25 | 2023-12-26 | Pharmacosmos Holding A/S | Stable iron oligosaccharide compound |
WO2012104204A1 (en) | 2011-01-31 | 2012-08-09 | Vifor (International) Ag | Iron-carbohydrate complex compounds for the intravenous therapy of malaria |
Also Published As
Publication number | Publication date |
---|---|
ATE445406T1 (de) | 2009-10-15 |
CR9300A (es) | 2007-12-07 |
AU2006212322A1 (en) | 2006-08-17 |
UA88347C2 (ru) | 2009-10-12 |
MX2007009588A (es) | 2007-09-12 |
SI1848446T1 (sl) | 2010-01-29 |
AU2006212322B2 (en) | 2012-01-19 |
DK1848446T3 (da) | 2010-02-15 |
CA2597154C (en) | 2011-03-15 |
PT1848446E (pt) | 2009-12-21 |
EP1848446B1 (de) | 2009-10-14 |
IL185020A0 (en) | 2007-12-03 |
RU2359680C2 (ru) | 2009-06-27 |
KR20070107106A (ko) | 2007-11-06 |
RU2007133509A (ru) | 2009-03-20 |
CY1109685T1 (el) | 2014-08-13 |
TNSN07307A1 (en) | 2008-12-31 |
PL1848446T3 (pl) | 2010-03-31 |
JP2008530049A (ja) | 2008-08-07 |
NO20074536L (no) | 2007-11-05 |
ZA200707716B (en) | 2008-06-25 |
BRPI0606974A2 (pt) | 2009-07-28 |
JP5060312B2 (ja) | 2012-10-31 |
CN101155593A (zh) | 2008-04-02 |
IL185020A (en) | 2013-10-31 |
US20080214496A1 (en) | 2008-09-04 |
HRP20100027T1 (hr) | 2010-02-28 |
EP1848446A1 (de) | 2007-10-31 |
US8722101B2 (en) | 2014-05-13 |
CA2597154A1 (en) | 2006-08-17 |
DE502006005100D1 (de) | 2009-11-26 |
ES2333814T3 (es) | 2010-03-01 |
US20140187514A1 (en) | 2014-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006084782A1 (de) | Verwendung von eisen(iii)-komplexverbindungen | |
EP1924270B1 (de) | Eisen(iii) komplex-verbindungen zur oralen behandlung von eisenmangel bei patienten mit chronischen entzündlichen darmerkrankungen | |
EP1944033B1 (de) | Verwendung von Pektinhydrolyseprodukten | |
EP2111416B2 (de) | Eisen-kohlenhydrat-komplex-verbindungen | |
EP1954314A2 (de) | Präparat, umfassend eisen(iii)-komplexverbindungen und redoxaktive substanz(en) | |
EP1429789B1 (de) | Antiinfektive kohlenhydrate | |
CH638819A5 (de) | Inklusionskomplex des cyclodextrins mit indomethacin und verfahren zur herstellung des komplexes. | |
DE69832722T2 (de) | Eisen-l-threonat-,pharmazeutische zusammensetzungen und deren verwendung zur verbesserung und behandlung von anämie bei menschen | |
DE3212817C2 (de) | ||
DE3424997C2 (de) | ||
DE4429735C2 (de) | Pflanzlicher Redoxkatalysator, Mittel zur Behandlung immunbiologischer Zellbelastungsschwächen und Verfahren zu dessen Herstellung | |
EP2606885A1 (de) | Wiederherstellung eines arzneimittelpräparats mit antibakterieller, antiulzeröser und immunmodulierender wirkung | |
DE60027760T2 (de) | Verwendung von substituierten nitrobenzol derivaten zur behandlung von erkrankungen verursacht von bakterien, pilzen und viren | |
DE1950403B2 (de) | Pharmazeutische Zusammensetzung auf der Basis von Formaldehyd-Casein | |
EP1295601A1 (de) | Arzneiform auf der basis einer nichtsteroidalen anti-inflammatorischen substanz | |
EP2044944A1 (de) | Nootropes medizinisches mittel | |
AT334525B (de) | Verfahren zur herstellung von menschlichem antistaphylokokkusimmunoglobulin | |
CN116731218A (zh) | 一种菌菇多糖提取物及其制备方法和用途 | |
DE2049938A1 (en) | Bile acid and triglyceride absorbing resins | |
DE3719124A1 (de) | Ein aminobenzoesaeurederivat enthaltendes mittel zum verhindern der anreicherung von sorbit in einem lebenden koerper | |
DE102010023626A1 (de) | Verwendung von Corrinoiden zur arzneilichen Anwendung bei Fell- und Hauterkrankungen bei Klein- und Groß-Tieren (warm- und kaltblütig), (z.B. bei Fischen, Vögeln, Pferden, Rindern, Kamelen, Hunden, Katzen, Reptilien) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006707742 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2597154 Country of ref document: CA Ref document number: 185020 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/009588 Country of ref document: MX Ref document number: 2007554530 Country of ref document: JP Ref document number: 12007501697 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2007-009300 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006212322 Country of ref document: AU Ref document number: 1020077020249 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007133509 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007/07716 Country of ref document: ZA |
|
ENP | Entry into the national phase |
Ref document number: 2006212322 Country of ref document: AU Date of ref document: 20060118 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006212322 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680011526.3 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2006707742 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11815568 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0606974 Country of ref document: BR Kind code of ref document: A2 |